Clinical TrialMay 14, 2026, 07:02 AM
Tiziana Reports Reduced Brain Inflammation in MSA Patients
AI Summary
Tiziana Life Sciences announced initial quantitative PET imaging results from the first two Multiple System Atrophy (MSA) patients in its Phase 2 clinical trial for intranasal foralumab. The results showed a marked reduction in brain inflammation, with up to approximately 35% reduction in standardized uptake value (SUV) and 24% reduction in standardized uptake value ratio (SUVR) in affected brain regions. This marks the third indication where intranasal foralumab has demonstrated reduced inflammation on PET scans, highlighting its potential for neurodegenerative conditions like MSA, which currently lacks approved disease-modifying treatments.
Key Highlights
- Foralumab is the first intranasal immune modulator in clinical trials for Multiple System Atrophy (MSA).
- Initial quantitative PET imaging results from the first two MSA patients in Phase 2 trial reported.
- Up to approximately 35% reduction in standardized uptake value (SUV) observed in affected brain regions.
- Approximately 24% reduction in standardized uptake value ratio (SUVR) observed in affected brain regions.
- Reductions in inflammatory activity were seen in basal ganglia and cerebellar white matter.
- This is the third indication showing marked reduction in inflammation on PET scans with intranasal foralumab.
- Currently, there are no approved disease-modifying treatments for MSA.
Price Impact
More from TLSA